In the company’s third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed expectations ... within our expectations,” the company said. Lilly’s stock has tumbled ...

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

The stock has also outperformed the sector as well as the S&P 500, as seen in the chart below. The stupendous success of Mounjaro and Zepbound has made Lilly the largest drugmaker with a market ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed ... the company said. Lilly's stock has tumbled 21.3% over the past three months ...